Alexis A Thompson

List of Publications by Year
in descending order

138 papers	3,265 citations	218677 26 h-index	168389 53 g-index
141 all docs	141 docs citations	141 times ranked	3649 citing authors

#	Article	IF	Citations
1	An update on the US adult thalassaemia population: a report from the CDC thalassaemia treatment centres. British Journal of Haematology, 2022, 196, 380-389.	2.5	4
2	Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. New England Journal of Medicine, 2022, 386, 617-628.	27.0	144
3	Clinical phenotypes of three children with sickle cell disease caused by <scp>HbS</scp>/Sicilian (Î²)⁰â€thalassemia deletion. American Journal of Hematology, 2022, 97, .	4.1	2
4	Betibeglogene Autotemcel Gene Therapy for Nonâ€“Î² ⁰ /Î² ⁰ Genotype Î²-Thalassemia. New England Journal of Medicine, 2022, 386, 415-427.	27.0	91
5	Metformin for treatment of cytopenias in children and young adults with Fanconi anemia. Blood Advances, 2022, 6, 3803-3811.	5.2	4
6	In Remembrance: Dr. Kwaku Ohene-Frempong. , 2022, 19, .		0
7	The pyruvate kinase (PK) to hexokinase enzyme activity ratio andÂerythrocyte PK protein level in the diagnosis and phenotype of PK deficiency. British Journal of Haematology, 2021, 192, 1092-1096.	2.5	15
8	A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy. Blood Advances, 2021, 5, 570-583.	5.2	38
9	Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2021, 325, 1513.	7.4	24
10	Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. JMIR Research Protocols, 2021, 10, e27650.	1.0	8
11	Time to rethink haemoglobin threshold guidelines in sickle cell disease. British Journal of Haematology, 2021, 195, 518-522.	2.5	7
12	Concordance with comprehensive iron assessment, hepatitis A vaccination, and hepatitis B vaccination recommendations among patients with sickle cell disease and thalassaemia receiving chronic transfusions: an analysis from the Centers for Disease Control haemoglobinopathy blood safety project. British Journal of Haematology, 2021, 195, e160-e164.	2.5	2
13	ASH Research Collaborative: a real-world data infrastructure to support real-world evidence development and learning healthcare systems in hematology. Blood Advances, 2021, 5, 5429-5438.	5.2	11
14	Consensus statement for the perinatal management of patients with Î± thalassemia major. Blood Advances, 2021, 5, 5636-5639.	5.2	6
15	Metformin for Treatment of Cytopenias in Children and Young Adults with Fanconi Anemia. Blood, 2021, 138, 1102-1102.	1.4	1
16	Rurioctocog Alfa Pegol Use in Immune Tolerance Induction: Interim Results from an Open-Label Multicenter Clinical Trial in Previously Untreated Patients with Severe Hemophilia a. Blood, 2021, 138, 3185-3185.	1.4	0
17	Polyclonality Strongly Correlates with Biological Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT). Blood, 2021, 138, 561-561.	1.4	3
18	Association between hospital admissions and healthcare provider communication for individuals with sickle cell disease. Hematology, 2020, 25, 229-240.	1.5	3

#	Article	IF	Citations
19	Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Advances, 2020, 4, 2058-2063.	5.2	93
20	Characterization of the severe phenotype of pyruvate kinase deficiency. American Journal of Hematology, 2020, 95, E281.	4.1	8
21	Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multiâ€center <scp>HGB</scp>â€206 trial. American Journal of Hematology, 2020, 95, E239-E242.	4.1	22
22	Parvovirus B19 infection in sickle cell disease: An analysis from the Centers for Disease Control haemoglobinopathy blood surveillance project. Transfusion Medicine, 2020, 30, 226-230.	1.1	5
23	A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent Î²-Thalassemia. New England Journal of Medicine, 2020, 382, 1219-1231.	27.0	177
24	Comorbid Medical Conditions in Young Athletes: Considerations for Preparticipation Guidance During the COVID-19 Pandemic. Sports Health, 2020, 12, 456-458.	2.7	8
25	A patientâ€centered medical home model for comprehensive sickle cell care in infants and young children. Pediatric Blood and Cancer, 2020, 67, e28275.	1.5	4
26	Understanding sickle cell disease: impact of surveillance and gaps in knowledge. Blood Advances, 2020, 4, 496-498.	5.2	4
27	Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy. Blood, 2020, 136, 16-17.	1.4	4
28	Long-Term Efficacy and Safety of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent Î²-Thalassemia: Results in Patients with up to 6 Years of Follow-up. Blood, 2020, 136, 51-52.	1.4	6
29	Favorable Outcomes in Pediatric Patients in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent Î²-Thalassemia. Blood, 2020, 136, 52-54.	1.4	7
30	Improvements in Health-Related Quality of Life for Patients Treated with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy. Blood, 2020, 136, 10-10.	1.4	5
31	Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the Believe Trial. Blood, 2020, 136, 8-9.	1.4	7
32	Addressing Recruitment Challenges in the Engage-HU Trial in Young Children with Sickle Cell Disease. Blood, 2020, 136, 26-27.	1.4	0
33	Response of Patients with Transfusion-Dependent Î²-Thalassemia (TDT) to Betibeglogene Autotemcel (beti-cel; LentiGlobin for Î²-Thalassemia) Gene Therapy Based on HBB Genotype and Disease Genetic Modifiers. Blood, 2020, 136, 1-3.	1.4	1
34	A Targeted Agent for Sickle Cell Disease â€" Changing the Protein but Not the Gene. New England Journal of Medicine, 2019, 381, 579-580.	27.0	1
35	Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study. Haematologica, 2019, 104, 1974-1983.	3.5	43
36	Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia. The Cochrane Library, 2019, 6, CD012900.	2.8	12

#	Article	IF	Citations
37	Combination Oral Chelation in Adult Patients With Transfusion-dependent Thalassemia and High Iron Burden. Journal of Pediatric Hematology/Oncology, 2019, 41, e47-e50.	0.6	9
38	Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica, 2019, 104, e51-e53.	3.5	46
39	Risk factors for hospitalizations and readmissions among individuals with sickle cell disease: results of a U.S. survey study. Hematology, 2019, 24, 189-198.	1.5	42
40	Northstar-2: Updated Safety and Efficacy Analysis of Lentiglobin Gene Therapy in Patients with Transfusion-Dependent Î²-Thalassemia and Non-Î²0/Î²0 Genotypes. Blood, 2019, 134, 3543-3543.	1.4	13
41	Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy. Blood, 2019, 134, 2061-2061.	1.4	7
42	Does Gene Therapy in Beta Thalassemia Normalize Novel Markers of Ineffective Erythropoiesis and Iron Homeostasis?. Blood, 2019, 134, 816-816.	1.4	3
43	Characterization of the Severe Phenotype of Pyruvate Kinase Deficiency. Blood, 2019, 134, 949-949.	1.4	0
44	Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency. Blood, 2019, 134, 2175-2175.	1.4	0
45	Pyruvate Kinase (PK) Protein and Enzyme Levels in the Diagnosis and Clinical Phenotype of PK Deficiency. Blood, 2019, 134, 3515-3515.	1.4	1
46	Clinical Practice Patterns for Hydroxyurea Initiation in Young Children with Sickle Cell Disease. Blood, 2019, 134, 4713-4713.	1.4	0
47	Beliefs about hydroxyurea in youth with sickle cell disease. Hematology/ Oncology and Stem Cell Therapy, 2018, 11, 142-148.	0.9	43
48	Epidemiologic and clinical characteristics of nontransfusionâ€dependent thalassemia in the United States. Pediatric Blood and Cancer, 2018, 65, e27067.	1.5	15
49	Physician decision making in selection of secondâ€line treatments in immune thrombocytopenia in children. American Journal of Hematology, 2018, 93, 882-888.	4.1	30
50	Gene Therapy in Patients with Transfusion-Dependent Î²-Thalassemia. New England Journal of Medicine, 2018, 378, 1479-1493.	27.0	525
51	Modifying factors of the health belief model associated with missed clinic appointments among individuals with sickle cell disease. Hematology, 2018, 23, 683-691.	1.5	23
52	Unrelated Donor Transplantation in Children with Thalassemia using Reduced-Intensity Conditioning: The URTH Trial. Biology of Blood and Marrow Transplantation, 2018, 24, 1216-1222.	2.0	23
53	Association between Participantsâ€™ Characteristics, Patient-Reported Outcomes, and Clinical Outcomes in Youth with Sickle Cell Disease. BioMed Research International, 2018, 2018, 1-8.	1.9	29
54	Current Results of Lentiglobin Gene Therapy in Patients with Severe Sickle Cell Disease Treated Under a Refined Protocol in the Phase 1 Hgb-206 Study. Blood, 2018, 132, 1026-1026.	1.4	23

#	Article	IF	Citations
55	Patient-Centered eHealth Interventions for Children, Adolescents, and Adults With Sickle Cell Disease: Systematic Review. Journal of Medical Internet Research, 2018, 20, e10940.	4.3	119
56	In a Global State of Mind. , 2018, 15, .		0
57	Hematology's Red Carpet for Innovation. , 2018, 15, .		0
58	ASH: A Year in Review. , 2018, 15, .		0
59	Seizing the Moment for Sickle Cell Disease. , 2018, 15, .		0
60	Health Related Quality of Life and Fatigue in Patients with Pyruvate Kinase Deficiency. Blood, 2018, 132, 4807-4807.	1.4	1
61	Association among sickle cell trait, fitness, and cardiovascular risk factors in CARDIA. Blood, 2017, 129, 723-728.	1.4	24
62	Healthâ€related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease. Pediatric Blood and Cancer, 2017, 64, e26369.	1.5	73
63	Feasibility and safety of home exercise training in children with sickle cell anemia. Pediatric Blood and Cancer, 2017, 64, e26671.	1.5	17
64	Barriers to hydroxyurea adherence and healthâ€related quality of life in adolescents and young adults with sickle cell disease. European Journal of Haematology, 2017, 98, 608-614.	2.2	62
65	Self-Reported Physical Activity and Exercise Patterns in Children With Sickle Cell Disease. Pediatric Exercise Science, 2017, 29, 388-395.	1.0	13
66	Making a case for more sickle cell initiatives in Africa. Blood, 2017, 129, 136-137.	1.4	1
67	Adherence to hydroxyurea, health-related quality of life domains, and patientsâ€™ perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults. Health and Quality of Life Outcomes, 2017, 15, 136.	2.4	69
68	Medication Adherence and Technology-Based Interventions for Adolescents With Chronic Health Conditions: A Few Key Considerations. JMIR MHealth and UHealth, 2017, 5, e202.	3.7	69
69	Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia. Cochrane Database of Systematic Reviews, 2017, 2017, .	0.5	0
70	New developments in the management of sickle cell disease. Blood Advances, 2016, 1, 3-3.	5.2	1
71	Toward understanding familyâ€related characteristics of young adults with sickleâ€cell disease or sickleâ€cell trait in the USA. Journal of Clinical Nursing, 2016, 25, 1587-1597.	3.0	6
72	Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Pediatric Blood and Cancer, 2016, 63, 1407-1413.	1.5	70

#	Article	IF	Citations
73	Unrelated donor stem cell transplantation for transfusionâ€dependent thalassemia. Annals of the New York Academy of Sciences, 2016, 1368, 122-126.	3.8	9
74	Barriers and facilitators to research participation among adults, and parents of children with sickle cell disease: A transâ€regional survey. American Journal of Hematology, 2016, 91, E461-2.	4.1	8
75	Management of Thalassemias. , 2016, , 39-51.		5
76	Technology Access and Smartphone App Preferences for Medication Adherence in Adolescents and Young Adults With Sickle Cell Disease. Pediatric Blood and Cancer, 2016, 63, 848-852.	1.5	107
77	Inâ€flight emergencies: Medical kits are not good enough for kids. Journal of Paediatrics and Child Health, 2016, 52, 363-365.	0.8	8
78	A framework for assessing outcomes from newborn screening: on the road to measuring its promise. Molecular Genetics and Metabolism, 2016, 118, 221-229.	1.1	19
79	Lentiglobin Gene Therapy for Transfusion-Dependent Î²-Thalassemia: Update from the Northstar Hgb-204 Phase 1/2 Clinical Study. Blood, 2016, 128, 1175-1175.	1.4	17
80	Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease. Blood, 2016, 128, 1176-1176.	1.4	42
81	The acute phase inflammatory response to maximal exercise testing in children and young adults with sickle cell anaemia. British Journal of Haematology, 2015, 171, 854-861.	2.5	17
82	Heart Rate Recovery Is Impaired after Maximal Exercise Testing in Children with Sickle Cell Anemia. Journal of Pediatrics, 2015, 166, 389-393.e1.	1.8	13
83	Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. British Journal of Haematology, 2015, 169, 887-898.	2.5	22
84	Update of Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral Beta AT87Q-Globin Vector (LentiGlobin BB305 Drug Product). Blood, 2015, 126, 201-201.	1.4	17
85	TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia. Blood, 2015, 126, 3-3.	1.4	19
86	Initial Results from Study Hgb-206: A Phase 1 Study Evaluating Gene Therapy By Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the Lentiglobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease. Blood, 2015, 126, 3233-3233.	1.4	11
87	Epidemiologic and Clinical Characteristics of Thalassemia (Thal) Intermedia (TI) in the United States. Blood, 2015, 126, 3279-3279.	1.4	1
88	Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of 20 New Variants. Blood, 2015, 126, 3337-3337.	1.4	4
89	Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing. Blood, 2015, 126, 73-73.	1.4	6
90	Health-related Smartphone Apps: Status Update for Hem-Onc Practitioners. , 2015, 12, .		0

#	Article	IF	Citations
91	The Phenotypic Spectrum of Pyruvate Kinase Deficiency (PKD) from the PKD Natural History Study (NHS): Description of Four Severity Groups By Anemia Status. Blood, 2015, 126, 2136-2136.	1.4	1
92	Neither Factor VIII Nor the Putative F8B Protein Is Detectable in Human Peripheral Blood Mononuclear Cells. Blood, 2015, 126, 3507-3507.	1.4	0
93	Evaluation of the SCKnowIQ Tool and Reproductive CHOICES Intervention Among Young Adults With Sickle Cell Disease or Sickle Cell Trait. Clinical Nursing Research, 2014, 23, 421-441.	1.6	25
94	Randomization is not associated with socio-economic and demographic factors in a multi-center clinical trial of children with sickle cell anemia. Pediatric Blood and Cancer, 2014, 61, 1529-1535.	1.5	9
95	Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood, 2014, 124, 2867-2871.	1.4	162
96	Habitual Physical Activity and Exercise Patterns in Children and Adolescents with Sickle Cell Disease. Blood, 2014, 124, 4099-4099.	1.4	2
97	Initial Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for Î²-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral Î²Î˙-T87Q -Globin Vector (LentiGlobin BB305 Drug Product). Blood, 2014, 124, 549-549.	1.4	10
98	Reproductive Health Choices for Young Adults With Sickle Cell Disease or Trait. Nursing Research, 2013, 62, 352-361.	1.7	37
99	Multicenter Investigation Of Unrelated Donor Hematopoietic Cell Transplantation (HCT) For Thalassemia Major After a Reduced Intensity Conditioning Regimen (URTH Trial). Blood, 2013, 122, 543-543.	1.4	9
100	The Inflammatory Response To Cardiopulmonary Exercise Testing In Children and Young Adults With Sickle Cell Anemia. Blood, 2013, 122, 2242-2242.	1.4	6
101	Sildenafil Therapy in Patients with Thalassemia and an Elevated Tricuspid Regurgitant Jet Velocity (TRV) On Doppler Echocardiography At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network. Blood, 2012, 120, 1023-1023.	1.4	2
102	Division (I): ASH Opposes NCAA Requirement for Screening. , 2012, 9, .		0
103	Cardiopulmonary and Laboratory Profiling of Patients with Thalassemia At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network.. Blood, 2012, 120, 2122-2122.	1.4	1
104	Heart Rate Recovery Is Impaired After Maximal Exercise Challenge in Pediatric Sickle Cell Anemia. Blood, 2012, 120, 3220-3220.	1.4	0
105	Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. British Journal of Haematology, 2011, 153, 121-128.	2.5	108
106	Primary Prophylaxis in Sickle Cell Disease: Is It Feasible? Is It Effective?. Hematology American Society of Hematology Education Program, 2011, 2011, 434-439.	2.5	5
107	Potential Immunogenicity of Amino Acid Sequences Encoded by Ns-SNPs in Factor VIII,. Blood, 2011, 118, 3329-3329.	1.4	1
108	Transfusion Complications in Thalassemia: A Report From the Centers for Disease Control and Prevention (CDC). Blood, 2011, 118, 340-340.	1.4	1

#	Article	IF	Citations
109	Refining Th Predictive Value of Secretory Phospholipase A2 In Sickle Cell Disease Patients with Acute Chest Syndrome. Blood, 2010, 116, 846-846.	1.4	2
110	Changes In Health Status and Quality of Life In Adults with Thalassemia: Year 1 Report of the Thalassemia Longitudinal Cohort Study.. Blood, 2010, 116, 1533-1533.	1.4	1
111	Response to Steroids Predicts Response to Rituximab In Pediatric Chronic Immune Thrombocytopenia.. Blood, 2010, 116, 3681-3681.	1.4	0
112	A Comparison of Two Pain Assessment Tools, the Adolescent Pediatric Pain Tool and PAINReportIt and Use of the Composite Pain Index in Sickle Cell Disease. Blood, 2010, 116, 2648-2648.	1.4	0
113	Changes In Health Status and Quality of Life In Parental Reports of Children with Thalassemia: Year 1 Report of the Thalassemia Longitudinal Cohort Study. Blood, 2010, 116, 257-257.	1.4	0
114	The North American Chronic Immune Thrombocytopenia Registry (NACIR): Demographics and Treatment Responses. Blood, 2010, 116, 2509-2509.	1.4	0
115	Radioulnar Synostosis and Its Hematology and Genetic Associations. Blood, 2010, 116, 2521-2521.	1.4	1
116	Pulmonary Hypertension in Thalassemia Assessed by Echocardiography: A Report From Baseline Data of the Thalassemia Clinical Research Network Longitudinal Cohort Study.. Blood, 2009, 114, 2016-2016.	1.4	3
117	Neuropathic Vs. Nociceptive Pain in Adolescent Sickle Cell Disease (SCD) Evaluated by a Computer-Based Self-Assessment Pain Tool.. Blood, 2009, 114, 2576-2576.	1.4	1
118	Elevated Systolic Blood Pressure and Low Fetal Hemoglobin Are Risk Factors for Silent Cerebral Infarcts in Children with Sickle Cell Anemia.. Blood, 2009, 114, 262-262.	1.4	5
119	Chelation Choices and Iron Burden Among Patients with Thalassemia in the 21st Century: a Report From the Thalassemia Clinical Research Network (TCRN) Longitudinal Cohort.. Blood, 2009, 114, 4056-4056.	1.4	5
120	Initial Liver Iron Predicts Cardiac Chelation Efficacy of Deferasirox (ExjadeÂ®) Monotherapy in Chronically Transfused Î²-Thalassemia (Î²-Thal) Patients: 18- and 24-Month Data.. Blood, 2009, 114, 4069-4069.	1.4	1
121	Symptoms of Anxiety and Depression Among Teens and Adults in the Thalassemia Longitudinal Cohort Study.. Blood, 2009, 114, 555-555.	1.4	20
122	The Utilization of a Computerized Pain Assessment Tool-PAINReportItÂ® in Adolescents with Sickle Cell Disease.. Blood, 2009, 114, 1535-1535.	1.4	1
123	Quality of Life in Adolescents and Adults with Thalassemia: A Report of the Thalassemia Longitudinal Cohort.. Blood, 2009, 114, 556-556.	1.4	0
124	Reliability of Tricuspid Regurgitant Jet Velocity Measurements in Children and Young Adults with Sickle Cell Disease.. Blood, 2009, 114, 2581-2581.	1.4	2
125	The Impact of the Child with Thalassemia On the Family: Parental Assessment by Child Health Questionnaire.. Blood, 2009, 114, 1371-1371.	1.4	1
126	Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone, 2008, 43, 162-168.	2.9	64

#	Article	IF	Citations
127	Deferasirox (ExjadeÂ®), the Once-Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5-Year Follow-up.. Blood, 2008, 112, 1420-1420.	1.4	10
128	Serum Ferritin Predicts Liver but Not Cardiac Iron Burden by Noninvasive MRI in Sickle Cell Disease		